A Phase I/IIa double blind single institute trial of low dose sirolimus for Pendred syndrome/ DFNB4
Latest Information Update: 13 Aug 2021
At a glance
- Drugs Sirolimus (Primary)
- Indications Congenital disorders; Ear disorders; Sensorineural hearing loss
- Focus Adverse reactions
- Acronyms PENDLRA
Most Recent Events
- 13 Apr 2021 Status changed from active, no longer recruiting to completed.
- 06 Jul 2020 Planned End Date changed from 28 Jul 2020 to 6 Jul 2020.
- 01 Jun 2020 New trial record